Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy

Phase 1 Terminated 13 enrolled The Methodist Hospital Research Institute Genentech, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase I study evaluating the safety of atezolizumab in combination with ADV/IL-12 gene therapy in patients with metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on first-line immunotherapy with or without chemotherapy.

Timeline

Start: 2021-10-14
Primary completion: 2024-08-01
Completion: 2025-04-01

Outcome

Outcome not reported

Stopped (Enrollment): “Poor accrual”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ADV/IL-12	Unknown	1e+11 vg	Other
Subject	ADV/IL-12	Unknown	3e+11 vg	Other
Subject	ADV/IL-12	Unknown	5e+11 vg	Other
Subject	Atezolizumab	Monoclonal antibody	1200 mg	Intravenous

Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy

Summary

Timeline

Outcome

Drugs

Indications